Overview

  • Product nameAnti-KCNQ1 antibody - Carboxyterminal end
    See all KCNQ1 primary antibodies
  • Description
    Rabbit polyclonal to KCNQ1 - Carboxyterminal end
  • Tested applicationsSuitable for: WB, ICC, IHC-P, IHC-FoFrmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow, Dog
  • Immunogen

    Synthetic peptide:

    SNTIGARLNRVEDKVTQLDQ

    , corresponding to C terminal amino acids 585-604 of Human KCNQ1

  • Positive control
    • Adult mouse ventricles.

Properties

Applications

Our Abpromise guarantee covers the use of ab77701 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
ICC
IHC-P
IHC-FoFr
  • Application notesICC: Use at an assay dependent dilution.
    IHC-FoFr: 1/500 - 1/1000.
    Note: dilute the antibody in PBS containing 5% normal goat serum, 0.2% Triton X-100 and 0.1% sodium azide.
    WB: 1/500 - 1/1000. Detects a band of approximately 72 kDa (predicted molecular weight: 75 kDa).


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionPotassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly deactivating potassium-selective outward current (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505). Promotes also a delayed voltage activated potassium current showing outward rectification characteristic (By similarity). During beta-adrenergic receptor stimulation participates in cardiac repolarization by associating with KCNE1 to form the I(Ks) cardiac potassium current that increases the amplitude and slows down the activation kinetics of outward potassium current I(Ks) (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505). Muscarinic agonist oxotremorine-M strongly suppresses KCNQ1/KCNE1 current (PubMed:10713961). When associated with KCNE3, forms the potassium channel that is important for cyclic AMP-stimulated intestinal secretion of chloride ions (PubMed:10646604). This interaction with KCNE3 is reduced by 17beta-estradiol, resulting in the reduction of currents (By similarity). During conditions of increased substrate load, maintains the driving force for proximal tubular and intestinal sodium ions absorption, gastric acid secretion, and cAMP-induced jejunal chloride ions secretion (By similarity). Allows the provision of potassium ions to the luminal membrane of the secretory canaliculus in the resting state as well as during stimulated acid secretion (By similarity). When associated with KCNE2, forms a heterooligomer complex leading to currents with an apparently instantaneous activation, a rapid deactivation process and a linear current-voltage relationship and decreases the amplitude of the outward current (PubMed:11101505). When associated with KCNE4, inhibits voltage-gated potassium channel activity (PubMed:19687231). When associated with KCNE5, this complex only conducts current upon strong and continued depolarization (PubMed:12324418). Also forms a heterotetramer with KCNQ5; has a voltage-gated potassium channel activity (PubMed:24855057). Binds with phosphatidylinositol 4,5-bisphosphate (PubMed:25037568).
      Isoform 2: Non-functional alone but modulatory when coexpressed with the full-length isoform 1.
    • Tissue specificityAbundantly expressed in heart, pancreas, prostate, kidney, small intestine and peripheral blood leukocytes. Less abundant in placenta, lung, spleen, colon, thymus, testis and ovaries.
    • Involvement in diseaseLong QT syndrome 1
      Jervell and Lange-Nielsen syndrome 1
      Atrial fibrillation, familial, 3
      Short QT syndrome 2
      Diabetes mellitus, non-insulin-dependent
    • Sequence similaritiesBelongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.1/KCNQ1 sub-subfamily.
    • DomainThe segment S4 is probably the voltage-sensor and is characterized by a series of positively charged amino acids at every third position.
      The coiled-coil domain mediates tetramerization.
      The segment S6 is involved in the inhibition of voltage-gated potassium channel activity by KCNE4.
      The C-terminal assembly domain promotes self-interactiona; allows functional channel.
    • Post-translational
      modifications
      Phosphorylation at Ser-27 by PKA; increases delayed rectifier potassium channel activity of the KCNQ1-KCNE1 complex through a macromolecular complex that includes PKA, PP1, and the targeting protein AKAP9.
      Ubiquitinated by NEDD4L; promotes internalization (PubMed:22024150). The ubiquitinylated form is internalized through a clathrin-mediated endocytosis by interacting with AP2M1 and is recycled back to the cell membrane via RAB4A and RAB11A (PubMed:23529131).
      Deubiquitinated by USP2; counteracts the NEDD4L-specific down-regulation of I(Ks) and restores the membrane localization.
    • Cellular localizationCell membrane. Cytoplasmic vesicle membrane. Early endosome. Membrane raft. Endoplasmic reticulum. Basolateral cell membrane. Colocalized with KCNE3 at the plasma membrane (PubMed:10646604). Upon 17beta-oestradiol treatment, colocalizes with RAB5A at early endosome (PubMed:23529131). Heterotetramer with KCNQ5 is highly retained at the endoplasmic reticulum and is localized outside of lipid raft microdomains (PubMed:24855057). During the early stages of epithelial cell polarization induced by the calcium switch it removed from plasma membrane to the endoplasmic reticulum where it retained and it is redistributed to the basolateral cell surface in a PI3K-dependent manner at a later stage (PubMed:21228319).
    • Information by UniProt
    • Database links
    • FormThere are 2 isoforms produced by alternative splicing. Isoform 2 also known as: TKvLQT1.
    • Alternative names
      • ATFB1 antibody
      • ATFB3 antibody
      • FLJ26167 antibody
      • IKs producing slow voltage-gated potassium channel subunit alpha antibody
      • IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1 antibody
      • Jervell and Lange-Nielsen syndrome 1 antibody
      • JLNS1 antibody
      • KCNA8 antibody
      • KCNA9 antibody
      • KCNQ1 antibody
      • KCNQ1_HUMAN antibody
      • kidney and cardiac voltage dependend K+ channel antibody
      • KQT-like 1 antibody
      • Kv1.9 antibody
      • Kv7.1 antibody
      • KVLQT1 antibody
      • long (electrocardiographic) QT syndrome, Ward-Romano syndrome 1 antibody
      • LQT antibody
      • LQT1 antibody
      • Potassium channel, voltage-gated, shaker-relatd subfamily, member 9 antibody
      • Potassium voltage-gated channel subfamily KQT member 1 antibody
      • potassium voltage-gated channel, KQT-like subfamily, member 1 antibody
      • RWS antibody
      • slow delayed rectifier channel subunit antibody
      • SQT2 antibody
      • Voltage-gated potassium channel subunit Kv7.1 antibody
      • WRS antibody
      see all

    Anti-KCNQ1 antibody - Carboxyterminal end images

    • All lanes : Anti-KCNQ1 antibody - Carboxyterminal end (ab77701) at 1 µg/ml

      Lane 1 : PANC-1 nuclear extract lysate (ab14882)
      Lane 2 : A498 (Human Kidney Carcinoma) Whole Cell Lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
      Developed using the ECL technique

      Performed under reducing conditions.

      Predicted band size : 75 kDa
      Observed band size : 74 kDa (why is the actual band size different from the predicted?)


      Exposure time : 150 seconds
    • Immunohistochemical analysis of PFA-fixed, paraffin embedded BALB/c murine ear tissue sections.

      KCNQ1 was stained, using ab77701 at 1/10 dilution, in the inner ear at the apical surface of marginal cells of stria vascularis (upper panel) and middle ear epithelium (lower panel). An AlexaFluor®488-conjugated IgG was used as the secondary antibody.

    References for Anti-KCNQ1 antibody - Carboxyterminal end (ab77701)

    This product has been referenced in:
    • Morris LM  et al. Mouse middle ear ion homeostasis channels and intercellular junctions. PLoS One 7:e39004 (2012). IHC-P ; Mouse . Read more (PubMed: 22720014) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab77701.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"